This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dendreon's Provenge Questioned in NEJM

The authors of the IMPACT study published in this week's NEJM found no outside variable, including use of the chemotherapy drug Taxotere, explains away the survival difference favoring Provenge.

Provenge is priced at $93,000 per course of treatment, which Longo labels as a "concern."

"The high cost may affect use. It is also uncertain what role sipuleucel-T Provenge will ultimately play in the treatment of prostate cancer, given the other promising treatments in development," he writes. Longo goes on to mention other prostate cancer drugs in late-stage clinical trials, including Johnson & Johnson's (JNJ) abiraterone and Medivation's (MDVN - Get Report) MDV3100.

"The prospects for improved therapy for prostate cancer have never been so encouraging, " Longo concludes at the end of his editorial. "The poor prognosis for men with prostate cancer will probably be substantially improved by the findings that emerge from ongoing clinical research."

David Miller of Biotech Stock Research, an independent biotech investment newsletter and a long-time follower of Dendreon, dismissed Longo's arguments as "mostly tired, ignorant or wrong."

Meantime, Dendreon will report financial results for the second quarter on Aug. 3. Analysts are expecting Provenge sales of approximately $4 million in the drug's first quarter since launch.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
DNDN $0.06 -6.02%
MDVN $128.32 -0.43%
AAPL $129.62 -2.20%
FB $79.34 -1.50%
GOOG $532.32 -1.44%

Markets

DOW 18,041.54 -190.48 -1.04%
S&P 500 2,104.20 -21.86 -1.03%
NASDAQ 5,032.7510 -56.6110 -1.11%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs